Buscar

Limitar los resultados
Buscar
Usar mi ubicación actual
Buscar

Tipo de servicio

Etiqueta

Número de resultados encontrados: 24
Use esta navegación adicional para ir a las páginas siguientes. Use las teclas de tabulación e Intro para navegar por el menú1 Página n.º 2 Navegar a la página siguiente Página 1 de 2
Saltee a 24 resultados encontrados. Página 1 de 2
    • Martes, 20 de abril de 2021

    Investigadores de Renown buscan participantes en el estudio de plasma de convaleciente

    Los médicos investigadores tratan de entender cómo responde el sistema inmunitario a la COVID-19 y crear un Nevada más saludable. Durante las primeras fases de la pandemia, el plasma de convalecencia se consideraba la única opción de tratamiento viable disponible para los pacientes con COVID-19. El plasma de convaleciente es el componente de la sangre de los pacientes recuperados que puede contener anticuerpos de COVID-19 que ayudan a combatir la infección. Desde entonces, los Institutos Nacionales de la Salud han elaborado directrices de tratamiento para la COVID-19 basadas en los datos de los estudios clínicos, y todavía se están realizando muchos estudios en todo el mundo que evalúan diversas opciones de tratamiento adicionales. El plasma de convaleciente tenía una gran demanda pero era difícil de localizar para los pacientes con COVID-19 en la zona del norte de Nevada. Austin Meegan, un auxiliar de enfermería de 24 años, fue hospitalizado y pasó semanas evitando la insuficiencia renal y pulmonar antes de enterarse de que cumplía los requisitos para recibir una transfusión de sangre experimental que parecía prometedora para el tratamiento de la COVID-19. Los médicos estimaron que Meegan solo tenía un 3 % de posibilidades de encontrar un donante compatible con su raro tipo de sangre. Thomas Gibson, un sobreviviente de la COVID-19 y residente de Texas con el mismo tipo de sangre, viajó a Reno para donar sus anticuerpos víricos y realizar una donación de plasma de convaleciente, la cual se cree que ayudó a salvar la vida de Meegan. Los investigadores clínicos y los científicos de Renown y de la Facultad de Medicina de la Universidad de Nevada, Reno (UNR Med) sabían que necesitaban crear mejores opciones para los pacientes y los médicos. Los investigadores clínicos desarrollaron un estudio para ayudar a otros pacientes como Austin, y solicitaron donaciones de pacientes recuperados de COVID-19 para que donaran su plasma de convaleciente. Los equipos de investigadores trataron de entender cómo responde el sistema inmunitario del cuerpo al virus a lo largo del tiempo, para ayudarles a desarrollar nuevos tratamientos para la COVID-19. “La capacidad del mundo para atravesar la crisis de la COVID dependerá de cuatro cosas: ciencia, tecnología, innovación y asociaciones”, dice el Dr. Tony Slonim, DrPH, presidente y director ejecutivo de Renown Health. “La capacidad del mundo para superar la crisis de la COVID dependerá de cuatro elementos: ciencia, tecnología, innovación y asociaciones, pero con UNR Med y nuestros socios, estamos haciendo grandes progresos en el avance de la investigación clínica que tiene el poder de salvar vidas y crear un estado de Nevada más saludable”. “Es tremendamente prometedor colaborar en la investigación clínica que no solo nos ayudará a entender mejor la enfermedad, sino que también ayudará a informar sobre el tratamiento para aquellos que combaten el COVID-19 que ha tenido un impacto tan devastador en los nevadenses, en nuestro país y en el mundo”, afirma Dean Thomas L. Schwenk, MD, de UNR Med. Renown, UNR Med y otros socios de atención médica del área colaboraron con Vitalant para recolectar plasma de donantes recuperados para un estudio sobre la eficacia del tratamiento. Los donantes elegibles tenían al menos 18 años, pesaban más de 110 libras y estaban sanos. Los donantes se habían recuperado completamente de un diagnóstico confirmado de COVID-19. Los coordinadores del proyecto en la Oficina de Investigación de Renown se vieron abrumados por el apoyo de la comunidad y las donaciones de plasma. Las asociaciones adicionales con el Distrito de Salud del Condado de Washoe, el estado de Nevada y la Oficina del Gobernador, Saint Mary’s Medical Center, Northern Nevada Medical Center, Carson Tahoe Health y VA Sierra Nevada Health Care System, junto con muchos proveedores de atención médica del área, ayudaron al equipo a alcanzar sus objetivos de inscribir a 120 participantes elegibles en el estudio. “Nuestro éxito en este estudio depende en gran medida del apoyo de nuestra gran comunidad, así como de la innovación y la colaboración demostradas por Renown y UNR Med”, afirmó Sara Healy, MD, MPH, investigadora principal del estudio y médica de enfermedades infecciosas pediátricas en Renown Children’s Hospital y UNR Med. “Estamos orgullosos de estar a la vanguardia respecto de la realización de investigaciones esenciales durante un tiempo tan importante de la historia, y esperamos que nuestra asociación se prolongue en el tiempo a medida que continuamos con esta importante labor”. “El control de la COVID-19 en nuestras comunidades depende de las pruebas. El estudio, que se está realizando para desarrollar una forma sensible, específica y más sencilla de recoger muestras (sangre), está avanzando en este campo y promete alcanzar nuestro objetivo común de tener la prueba de diagnóstico correcta para la situación clínica correcta en el momento correcto”, explica Mark Riddle, MD, DrPH, FISTM, investigador asociado del estudio, decano asociado de Investigación Clínica y profesor del Departamento de Medicina Interna e Investigación Médica de UNR Med. El equipo de investigación pide ahora a los residentes del área que participen en un estudio para analizar la eficacia de dos pruebas de detección de la COVID-19. Los participantes se someterán a dos análisis de sangre: uno de ellos consiste en una punción digital para obtener los resultados de una prueba rápida, y el otro consiste en una venopunción tradicional que confirma la presencia o ausencia de anticuerpos contra la COVID-19. Este estudio es una colaboración con InBios International, Inc. una empresa líder en biotecnología con sede en Seattle. Los investigadores buscan: Personas que han dado positivo para COVID-19 y que se han recuperado recientemente del virus. Los participantes del estudio deben estar en un período de entre 7 y 28 días posteriores al inicio de sus síntomas. Personas que recientemente hayan dado negativo para COVID-19 y nunca hayan dado positivo. Los interesados en participar en el estudio pueden ponerse en contacto con los coordinadores del proyecto en la Oficina de Investigación de Renown al (775) 982-3646, o por correo electrónico a covidplasmascreening@renown.org, de lunes a viernes, de 7:30 a.m. a 5:00 p.m. Se anima a las personas de entre 18 y 75 años con buena salud en general a que consideren la posibilidad de participar en este estudio en curso. No hay costo alguno por participar en este estudio y la participación es voluntaria. Su decisión de participar no afectará sus relaciones actuales o futuras con sus proveedores de atención médica, con el distrito de salud ni con la comunidad. Aquellos que decidan participar son libres de retirarse en cualquier momento. “El tiempo es vital cuando se trata de la COVID-19. Si podemos entregar los resultados de las pruebas a las personas y sus médicos de manera más oportuna, podremos hacer un diagnóstico más rápido del estado de salud de un paciente”, explica Christopher M. Kozlowski, MD, MHA, funcionario de Investigación Institucional de Renown y director médico/vicepresidente del Renown Institute for Heart & Vascular Health. “A medida que perfeccionamos la precisión de nuestras pruebas, aplicamos las pruebas de sensibilidad y especificidad para obtener resultados verdaderos negativos y verdaderos positivos. Esto proporciona a las personas resultados más oportunos y precisos y una atención de calidad mejorada”.     Acerca de Renown Health Renown Health es una red de atención médica integrada de administración local y sin fines de lucro que brinda servicios al norte de Nevada, Lake Tahoe y el noreste de California. Renown es uno de los mayores empleadores privados de la región y cuenta con una fuerza laboral de más de 7,000. Abarca tres hospitales de cuidados intensivos, un hospital de rehabilitación, el grupo médico y la red de atención de urgencias más integrales del área, y la compañía de seguro sin fines de lucro de propiedad local más grande de la región, Hometown Health. Renown tiene una larga trayectoria y un compromiso de larga data con la mejora de la atención y la salud de nuestra comunidad.     Acerca de la Facultad de Medicina de la Universidad de Nevada, Reno La Facultad de Medicina de la Universidad de Nevada, Reno (UNR Med), la primera facultad de medicina pública de Nevada, es una facultad basada en la comunidad, con un gran énfasis en la investigación y una visión a nivel estatal de un estado de Nevada saludable. Fundada en 1969, la UNR Med está mejorando la salud y el bienestar de todos los residentes de Nevada y sus comunidades mediante excelencia en la educación estudiantil, capacitación de posgrado y atención clínica, investigación con impacto local, nacional y global y una cultura de diversidad e inclusión. Para obtener más información, visite med.unr.edu.

    Leer más Acerca de Investigadores de Renown buscan participantes en el estudio de plasma de convaleciente

    • Miércoles, 05 de octubre de 2022

    Centro de Investigación Clínica recientemente ampliado en UNR Med fomenta la colaboración y la investigación con Renown Health

    Renown Health y University of Nevada, Reno School of Medicine (UNR Med) se enorgullecen en anunciar un espacio de investigación recientemente integrado y ampliado llamado Centro de Investigación Clínica (Clinical Research Center, CRC). Este espacio ofrece una ubicación física dinámica en el campus de la Universidad de Nevada, Reno, que apoya a la empresa de investigación UNR Med y Renown Health. “La asociación entre Renown Health y UNR Med realmente no conoce límites, y este Centro de Investigación Clínica es un ejemplo increíble de esa infinita posibilidad”, dijo Thomas Graf, MD, director ejecutivo interino de Renown Health. “Este nuevo espacio solo continuará expandiendo el acceso de nuestra comunidad a la investigación clínica como parte de la atención al paciente mientras proporciona los recursos necesarios para involucrar a nuestros estudiantes y apoyar un Nevada saludable”. Las capacidades de este espacio incluyen personal experimentado con conocimientos y habilidades en la puesta en funcionamiento de estudios de investigación clínicos y traslacionales no regulados por la FDA en una clínica de investigación centralizada de 5,470 pies cuadrados ubicada en el Centro de Medicina Molecular (Center for Molecular Medicine, CMM) de la Universidad. Este espacio de CRC proporciona recursos que incluyen: Una ubicación centralizada junto al espacio de laboratorio que permite la colaboración interdisciplinaria estratégica entre médicos y científicos básicos. Once habitaciones privadas para pacientes ambulatorios para visitas a la clínica de investigación. Dos estaciones de extracción de sangre. Áreas de consulta con el médico. Sala de conferencias para monitoreo y consultoría de ensayos. Asegurar el almacenamiento y la preparación del producto en investigación. Procesamiento y almacenamiento de muestras, incluidas centrífugas refrigeradas de encimera, refrigeradores y congeladores de 4°, -20° y -80° C. Las operaciones en torno a la investigación clínica se están volviendo más complejas, por lo que el crecimiento de la investigación clínica en nuestra comunidad requerirá experiencia y un espacio dedicado donde la investigación clínica se pueda realizar primero en un entorno de aprendizaje”, dijo Danielle Eaton, directora de Investigación Clínica de UNR Med y Renown Health. “Este centro de investigación clínica proporciona dicho espacio y personal experimentado donde estos estudios de investigación pueden completarse con éxito. El CRC proporciona un entorno de capacitación para estudiantes, residentes, cuerpo docente y personal profesional de investigación clínica que será necesario para llevar diagnósticos, tratamientos y preventivos de vanguardia a nuestra comunidad”. Conozca al equipo: Danielle Eaton, Directora médica de investigación clínica de UNR, Kristen Gurnea, Gerente de Investigación Clínica de Renown Health, Amber Emerson, Valerie Smith, gerente de proyectos de UNR Med, Annie Beach-Hills, gerente administrativa del UNR Med Center, Gina Castro, Michelle Mejia y Amil Trujillo-King, Coordinadores del estudio de UNR Med, Dr. John Westhoff, Presidente de Medicina Interna de UNR Med, Médico de medicina de emergencia, Dr. Sean Kandel, UNR Med Director asociado del programa de investigación para residentes, Profesor adjunto de Medicina Interna, Dr. Amneet Rai, Farmacéutica de investigación clínica de UNR Med, Dra. Kellie Watkins, Epidemiólogo clínico/gerente de datos/estadístico de UNR Med Como parte de la afiliación entre UNR Med y Renown Health, la Oficina de Investigación Clínica es parte de una Oficina de Investigación Clínica integrada, lo que permite que ambas entidades colaboren en los objetivos compartidos del programa de investigación. Este esfuerzo permite que los colegas se asocien en investigaciones clínicas y aprovechen la investigación y la prestación de atención médica de vanguardia a los nevadenses del norte. Acerca de Renown Health Renown Health es la red de atención médica integrada de administración local y sin fines de lucro más grande de la región, que presta servicios a Nevada, Lake Tahoe y el noreste de California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Actualmente, Renown está inscribiendo participantes en el estudio genético de salud poblacional basado en la comunidad más grande del mundo, el Healthy Nevada Project®. Acerca de UNR Med La Universidad de Nevada, Reno School of Medicine (UNR Med), la primera escuela de medicina pública de Nevada, es una escuela de medicina comunitaria intensiva en investigación con una visión estatal para una Nevada saludable. Desde 1969, UNR Med ha capacitado a más de 3,900 estudiantes, residentes y becarios. La UNR Med continúa mejorando la salud y el bienestar de todos los residentes de Nevada y sus comunidades mediante excelencia en la educación estudiantil, capacitación de posgrado y atención clínica, investigación con impacto local, nacional y global, y una cultura de diversidad e inclusión. Para obtener más información, visite med.unr.edu.

    Leer más Acerca de Centro de Investigación Clínica recientemente ampliado en UNR Med fomenta la colaboración y la investigación con Renown Health

    • COVID-19
    • Vacunas
    • Virus

    Vacunas de refuerzo contra la COVID-19, lo que debe saber

    Getting the COVID-19 booster is the best way to protect yourself from severe illness or death due to COVID-19, and both the CDC and the FDA have approved booster shots for people ages 18 and older. So, with the holidays right around the corner and infection rates on the rise both in Nevada and nationally, the best thing you can do to prevent the continued spread of this deadly virus is to get boosted today. The Basics: Who: It is recommended that everyone 18 years or older get a COVID-19 booster shot. When: At least 6 months after completing your primary COVID-19 vaccination series. What: Any of the COVID-19 vaccines authorized in the United States. The CDC allows for mix and match dosing for booster shots. How: To make an appointment for your COVID-19 vaccine booster, please visit vaccines.gov today. Appointment Reminders: Don’t forget to bring your CDC vaccination record card to your appointment. Refresh yourself on the potential side effects and remember that these are normal signs your body is building up protection. Commonly Asked Questions: Q: Does anything change if I received the Johnson & Johnson as my first COVID-19 vaccine? A: If you received the Johnson & Johnson COVID-19 vaccine, you are elidable for a booster two months after completing your primary vaccine. Q: Is the formula the same for the boosters as it was for the primary vaccine? A: COVID-19 booster shots are the same formulation as the current COVID-19 vaccines. However, in the case of the Moderna COVID-19 vaccine booster shot, it is half the dose of the vaccine people get for their primary series. Q: Am I still considered “fully vaccinated” if I don’t receive a COVID-19 booster shot. A: Yes, everyone is still considered fully vaccinated two weeks after their second dose in a two-shot series, such as the Pfizer-BioNTech or Moderna vaccines, or two weeks after a single-dose vaccine, such as the J&J/Janssen vaccine. All information courtesy of the Center for Disease Control and Prevention. All information courtesy of the Center for Disease Control and Prevention

    Read More About COVID-19 Booster Shots, What You Need to Know

    • Atención del cáncer
    • Ensayos clínicos
    • Investigación y estudios

    Sobreviviente del cáncer de ovario cuenta cómo decidió probar con ensayos clínicos

    While there used to be three basic treatment options for cancer -- surgery, radiation and chemotherapy, or a combination of the three -- there's a fourth option: clinical trials. Here, a Renown patient shares her successful battle with ovarian cancer, aided by a clinical trial. Shari Flamm's battle with ovarian cancer began in 2011. She was experiencing prolonged bleeding, irregular thyroid levels and anemia and was scheduled to undergo a hysterectomy. Before the surgery, her gynecologist ran routine tests to check for cancer as a precautionary measure. All tests were negative for cancer, expect her CA 125 test. A CA 125 test measures the amount of the protein CA 125 (cancer antigen 125) in the blood. In some cases, a CA 125 test may be used to look for early signs of ovarian cancer in women with a very high risk of the disease. In most laboratories, the normal level is 0 to 35 units/ml. Flamm's CA 125 level was 121. As Flamm can attest, early diagnosis played a key role in her battle with ovarian cancer. September is Gynecologic Cancer and Ovarian Cancer Awareness Month – an important time to learn the signs, symptoms and risk factors of this type of cancer so your doctor can diagnosis the disease as early as possible. Ovarian Cancer: Round One Despite the elevated CA 125 results, her doctor recommended they move forward with the hysterectomy. But when surgery began, doctors discovered a mass. She had stage 4 cancer. The procedure was halted, the mass was biopsied and she was immediately seen by Dr. Peter Lim of the The Center of Hope. Following diagnosis, Flamm underwent surgery with Dr. Lim to remove the cancer, which had spread to part of diaphragm, spleen, colon and other organs. Three months after surgery, Flamm had recovered enough to start six rounds of chemotherapy in her hometown of Carson City. She continued working at a doctor's office during her treatment, and was grateful for Dr. Lim’s ability to co-manage her care so she could stay close to work and family. “To me, chemo was the scariest part because I didn’t like feeling sick,” Flamm says. Thankfully, her body responded well to the treatments and she was back to the things she loved. “I stated working out at the gym, even if it was only for 10 minutes,” she says. She also stayed positive by spending time with her grandchildren, attending a San Jose Sharks hockey game, going for walks and enjoying concerts. Ovarian Cancer: Round Two In November 2014, Flamm had a cancer check-up. That’s when doctors discovered three cancerous tumors. For this round, Flamm choose another treatment option -- clinical trials at Renown Institute for Cancer. Clinical trials are the studies that test whether drugs work, and inform doctors' decisions about how to treat their patients. Flamm participated in a clinical trial that featured oral-targeted therapy stronger than IV chemotherapy. The hope was for the drug to shrink her tumors, however the result was stabilization -- meaning the lumps weren’t growing or spreading. The best part of the clinical trial, Flamm says, was the constant monitoring. Between the CT scans every six weeks, a heart scan every three months and monthly doctor visits, she was confident that if the cancer started growing or spreading, her healthcare team would catch it right away. For Flamm, the benefits of the clinical trial included less hair loss, less fatigue and more time to focus on what’s important in her life -- her family. “I decided I wasn’t going to be that sick grandma on the couch with cancer,” Flamm says. After taking the oral medication for one year, Flamm developed a rash and discontinued treatment due to discomfort. Clinical Trials, Setbacks and Survival In June 2016, two of the three tumors began to grow and had to be surgically removed. Despite the setback, Flamm was determined to maintain a positive outlook. "You have to stay positive because cancer feeds off anger, depression and stress," Flamm says. Flamm was released to go home with clear margins, meaning the tumors were removed and are surrounded by a rim of normal tissue that does not have cancerous cells. Flamm says her outlook on life has changed drastically since her first cancer diagnosis. “Your whole mentality changes when cancer disturbs your life," Flann says. "The things that weren’t important, are now ever so important. I’m a lot calmer now,” Flamm says.

    Read More About Ovarian Cancer Survivor Shares Decision to Try Clinical Trial

    • Farmacia
    • Consumo de drogas
    • Medicamentos

    Medicamentos genéricos: lo que debe saber sobre ellos

    Without a doubt, taking medications can not only be expensive, but also confusing. In the United States, generic prescriptions are widely used, with 9 out of 10 people choosing them over a name brand. Pharmacists are a great resource to help us understand the benefits and side effects of any medication. We asked Adam Porath, PharmD, Vice President of Pharmacy at Renown Health, to answer some common questions about generic drugs. What is a generic drug? A generic drug has the same active ingredients of brand-name drugs. Brand-name drugs have a patent (special license) protecting them from competition to help the drug company recover research and development costs. When the patent expires other manufacturers are able to seek approval for a generic drug. However, the color, shape and inactive elements may be different. Per the U.S. Food & Drug Administration (FDA), a generic medicine works in the same way and provides the same clinical benefit as its brand-name version. Why do they cost less? Generic drug makers do not have the expense of costly development, research, animal and human clinical trials, marketing and advertising. This savings is passed on to the public. Also after a patent expires, several companies will compete on a generic version of a drug, further driving down prices.

    Read More About Generic Drugs – What You Need to Know About Them

    • COVID-19
    • Renown Health
    • Virus

    Viuda de Reno inspira una nueva política de visitantes para Renown

    Renown Health is one of the country’s first health systems to lift visitor restrictions for patients with COVID-19 and encourage the family to be at the patient’s bedside. Read Darlene and Dave’s story to understand why we’re updating our visitor policy. Dave and Darlene Randolph found joy in exploring antique shops and garage sales to find damaged or discarded vintage pieces. Dave would spend many hours scraping, cleaning, sanding, and refinishing items, transforming them into functional, beautiful pieces of furniture. Every piece in their home rekindles a memory and has a story to tell. On Thanksgiving, when Dave was too ill to gather around their antique dining room table, Darlene called the ambulance. Ailing with COVID-19 for two weeks, Dave had not been improving. When the EMTs reached her home and asked Darlene what underlying conditions he had, she said, “all of them.” David was seriously ill. Hospitalized for COVID-19, their communications options were limited. The only way Darlene could communicate with Dave was on a video call or by telephone. Dave spent 17 days hospitalized at Renown Regional Medical Center in Reno. Darlene spent 17 days waiting by the phone for more information on his condition. Darlene said he had “up days and down days,” but thought he might be home, sitting at their antique dinner table for Christmas. Sadly, Dr. David Randolph lost his battle with COVID-19 on December 13, 2020, and died as he slept in a hospital bed. When Darlene wrote his obituary for the newspaper, she gave thanks to the “tremendous nurses and doctors at Renown Regional Medical Center, for providing his care during a time when the family could not be with him.” Taking Action to Inspire Change Darlene wished she could have been there. Over their 45-year marriage, she had always been there. Darlene said, “I had always been at his bedside, as his advocate, to help communicate and straighten things out.” As a registered dietician, she worked in hospitals, knew the protocol, and knew that Renown had a restricted visitor policy to stop the virus’s spread- to other patients, staff, and their family members. Still, she wished she could have spent more time with him. On Christmas Eve, she sat down and wrote to Renown leadership. “As the wife of a COVID patient who recently passed away in your hospital, I want to express my thanks to you and your staff for the care he received in the last days of his life. I am aware that the nurses and staff are working under dangerous conditions and risking their health and lives by caring for multiple COVID patients. The staff is gracious, concerned, and doing everything they can.” She continued, “I know procedures are changing every hour to try to stay ahead of this dangerous virus, and I am sharing my experiences, hoping they will be helpful when establishing policies that impact families.” Darlene explained that despite receiving assurances that Dave’s nurse or a doctor would call daily, sometimes they would forget. She explains in her letter, “how important it is, in these times when the family cannot visit, and has only infrequent communication and is anxiously waiting at home for information about their loved one, how much it means to get a call from someone caring for him at the hospital. If there is a way you can help assure nurses have time to make calls or assist patients in making calls because it is an important part of patient care.” A Person-Centered Visitor Policy After receiving her letter, Renown leadership called Mrs. David Randolph to thank her, offer his sympathies and ask if Renown could help in any way. Darlene asked if he might reconsider allowing families to visit hospital patients during treatment for COVID-19. As the COVID-19 situation has evolved, the policy has as well. Renown hospitals and medical practices now encourage limited visitors for all patients, including those diagnosed with COVID-19. Renown also has extra safety measures to protect the health of patients, visitors and healthcare employees. Darlene is very pleased that her letter inspired this shift in visitor policies for patients with COVID-19. She says, “I have always tried to think of ways I could help other families. Especially those senior couples where one has been hospitalized and the other is home. My wish is to help others.” Renown Health Visitor Policy Renown Health patients may identify two healthy adult “patient supporters” to accompany them on their hospital stay. For more details, visit our Patient Supporter Guidelines page.

    Read More About Reno Widow Inspires New Visitor Policy for Renown

    • COVID-19
    • Farmacia
    • Vacunas
    • Virus

    Farmacéuticos responden preguntas sobre las vacunas contra la COVID-19

    Vaccines that provide protection against the COVID-19 virus are bringing us closer to the end of this deadly pandemic. Two different COVID-19 vaccines are currently available in the U.S. today: one from Pfizer and the other from Moderna. Kate Ward, PharmD, BCPS, Director of Clinical Pharmacy at Renown Health and Adam Porath, PharmD, Vice President of Pharmacy at Renown, share what you need to know about these vaccines. When two COVID-19 vaccines were approved by the U.S. Food & Drug Administration (FDA) in December 2020, it was cause for celebration. Why? Because according to the CDC, the vaccines are 94 percent or more effective in providing protection against the COVID-19 virus! Many people are seeking information about the new Moderna and Pfizer vaccines. Below, our pharmacy leaders provide answers to some commonly asked questions. How do the COVID-19 Vaccines Work? The Pfizer and Moderna vaccines are both mRNA vaccines that help your immune system develop antibodies against the COVID-19 virus. The vaccines use messenger RNA, or mRNA, to show our bodies’ protein-making cells how to make the spike proteins of the COVID-19 virus. Our immune system reacts to these spike proteins by creating antibodies that can recognize and destroy them. So when a person is exposed to the virus in the future, they will be less likely to get sick. What are the Differences between the Pfizer and Moderna Vaccines? The Pfizer and Moderna COVID-19 vaccines are very similar, with just a few small differences worth noting. The main difference between the two vaccines is when you should receive your follow-up dose. Patients who receive a first dose of Pfizer should receive their second dose about three weeks later. Those who receive a first dose of Moderna should receive their follow-up vaccination roughly four weeks after their first dose. People 18 years and older can receive the Moderna vaccine while people 16 years and older can receive the Pfizer vaccine. Dosage for the Moderna vaccine is 0.5 ml (100 mcg). Dosage for the Pfizer vaccine is 0.3 ml (30 mcg).

    Read More About Pharmacists Answer Questions about the COVID-19 Vaccines

    • COVID-19
    • Vacunas
    • Virus

    Asesoramiento experto en vacunas contra el COVID-19

    With front-line workers receiving the first COVID-19 vaccinations, many of us are feeling hope, but also worry. As a result, we are joining with the Ad Council, the COVID Collaborative, HHS, CDC and NIAID (along with top health and medical organizations) to address your vaccine concerns and questions. Will the vaccine be available to everyone in Nevada? The Nevada Department of Health and Human Services (DHHS) is collaborating with health systems about the use of initially available, limited supplies of COVID-19 vaccines. They will provide guidance on the prioritization order of who will receive the vaccine. This will be based on available quantities, high-risk locations of work and certain other risk factors, and recommendations and guidance for public health agencies. The CDC has provided guidance to initially focus on the following groups: Healthcare personnel likely to be exposed to or treat people with COVID-19, nursing home residents and others in institutional settings; People at risk for severe illness from COVID-19 due to underlying medical conditions; People 65 years of age and older; Other essential workers. I worry the vaccine has been rushed The U.S. national vaccine safety system ensures that all vaccines are as safe as possible, and because vaccines are given to millions of healthy people to prevent serious diseases, they’re held to very high safety standards. COVID-19 vaccines are undergoing a rigorous development process that includes vaccinating tens of thousands of people who participate in a study to generate the needed clinical data. These clinical trials generate scientific data for the FDA to determine the safety and efficacy of each vaccine. It’s worth noting that the clinical studies to establish the safety and efficacy of the Covid-19 vaccines were as big and thorough as recent studies for other licensed vaccines (for example, the shingles vaccine). I'm concerned about the vaccine's side effects The most common side effects are very similar to those seen with most vaccines, such as: sore arms, fevers, and tiredness within 72 hours after the vaccine. These side effects usually mean that the vaccine is generating an immune response, indicating it is working. Short-term side effects observed in the leading COVID-19 vaccine trials include: Injection site pain and redness Fatigue Muscle aches and pains Joint pain Headache I’m afraid I’ll get COVID-19 from the vaccine None of the authorized and recommended COVID-19 vaccines, or COVID-19 vaccines currently in development in the United States, contain the live virus that causes COVID-19. This means that a COVID-19 vaccine cannot make you sick with COVID-19. Can children receive the COVID-19 vaccine? Not at the moment. In early clinical trials for various COVID-19 vaccines, only non-pregnant adults at least 18 years of age participated. However, clinical trials continue to expand those recruited to participate. The groups recommended to receive the vaccines could change in the future. As of now, it is recommended that children do not receive the vaccine. More information will be available from the vaccine manufacturers. I do not believe vaccines are effective Both this disease and the vaccine are new. We don’t know how long protection lasts for those who get infected or those who are vaccinated. What we do know is that COVID-19 has caused very serious illness and death for a lot of people. If you get COVID-19, you also risk giving it to loved ones who may get very sick. Getting a COVID-19 vaccine is a safer choice. The FDA is responsible for making sure that, just like any other medications, any FDA-authorized or approved COVID-19 vaccines are safe and they work. The EUA (Emergency Use Authorization) will not be provided if the FDA feels that the vaccine is unsafe. I can't get vaccines to due to a medical condition Adults of any age with certain underlying medical conditions are at increased risk for severe illness from the virus that causes COVID-19. mRNA COVID-19 vaccines may be administered to people with underlying medical conditions provided they have not had a severe allergic reaction to any of the ingredients in the vaccine. The following information aims to help people in the groups listed below make an informed decision about receiving the mRNA COVID-19 vaccine. It is extremely important to speak with your doctor regarding your specific medical condition, and always follow their strict advice regarding the COVID-19 vaccine, or any other vaccines. Sources: Renown COVID-19 Ad Council COVID Collaborative U.S. Department of Health & Human Services Centers for Disease Control and Prevention National Institute of Allergy and Infectious Disease

    Read More About COVID-19 Vaccine Expert Advice

    • Atención primaria
    • Salud pública
    • Virus

    Monkeypox: Un experto de Renown pesa

    Renown Health is closely following the national outbreak of the monkeypox virus and urging healthcare providers to be alert for patients with illnesses associated with a rash. In working with the Washoe County Health District (WCHD), Renown is closely monitoring the spread of monkeypox in the community and looking to prevent and reduce the spread of monkeypox. To help to ease worries, we consulted with Paul De Leon, Infection Preventionist at Renown Health. What Exactly is Monkeypox? Monkeypox is a rare viral illness caused by the monkeypox virus — the same family of viruses that causes Smallpox. Although symptoms are similar to Smallpox, monkeypox symptoms are milder and rarely fatal. However, it's important to mention that this virus can be more severe for these susceptible groups: Immunocompromised Pregnant women A fetus or newborn baby Women who are breastfeeding Young children Those with severe skin diseases such as eczema How is Monkeypox Transmitted? The monkeypox virus is not easily transmitted but occurs through sustained person to person close contact with an infected individual. Monkeypox can also be transmitted through direct contact with infectious rash, scabs, or body fluids. Monkeypox can also be spread through prolonged intimate physical contact, such as kissing, cuddling or sex. Lastly, monkeypox can be spread through contaminated linens or bedding. Transmission through respiratory secretions is uncommon but has been reported after prolonged face-to-face contact with symptomatic individuals. In addition, pregnant women can spread the virus to their fetuses through the placenta. Monkeypox Testing If you think you have monkeypox, contact your primary care physician or other medical providers to obtain testing. Notify the provider ahead of time before entering the physical office. Signs & Symptoms This current outbreak of West African monkeypox does not have the typical presentation of classic monkeypox. Symptoms usually appear one to three weeks after infection and include: Pimple-like rash or blisters on the face, inside the mouth, and on other areas of the body, like the hands, feet, chest, genitals, or anus. The rash will go through serval stages, including scabs, before healing and may be painful or itchy. Other symptoms of monkeypox can include: Fever Headache Muscle aches and backache Swollen lymph nodes Chills Exhaustion Respiratory symptoms such as sore throat, nasal congestion, or cough Symptoms of monkeypox may occur before or after a rash with some individuals only report experience a rash. Individuals with monkeypox are infectious once symptoms begin and remain infectious until lesions form scabs, scabs fall off, and a fresh layer of skin forms. The illness typically lasts 2-4 weeks.

    Read More About Monkeypox: A Renown Expert Weighs In

    • Ensayos clínicos
    • Investigación y estudios

    ¿Qué significa participar en un estudio clínico?

    Participating in a clinical trial is voluntary and a personal choice. Clinical trials are research studies that involve people and are an important part of patient care. What is a clinical trial?  Clinical trials are research studies that involve people, and they are an important part of patient care. There are several different types of clinical trials; some are designed to understand trends in a disease or identify better ways to diagnose a condition, while others determine if a new treatment is safe and works when treating, improving or preventing a health condition. There are over 400,000 clinical trials currently being conducted in the United States, and even more across the world. This includes health conditions such as heart failure, cancer, Parkinson’s Disease, respiratory conditions like COPD, common infections, cystic fibrosis, and many more. Clinical trials lead the healthcare industry to new discoveries that contribute to reliable and exact care, improving healthcare quality and saving lives. Clinical trials are conducted by a team of researchers, including doctors, pharmacists and clinical research coordinators. These research teams are highly skilled in their specialty areas, often providing traditional patient care and seeing research patients in the same day. These teams are responsible for making sure the clinical trial is completed correctly, and their patients are their top priority. Why should I consider participating in a clinical trial? Participating in a clinical trial is voluntary and a personal choice. There are many reasons why patients decide to get involved in clinical research. While many clinical trials are designed for patients who have a certain health condition, many studies also ask healthy volunteers to contribute in order to compare health outcomes. Clinical trials are also for patients at all different stages of their diagnosis. Depending on the specific study, the patient may receive access to a new cutting-edge treatment before it is widely available. When patients join a clinical trial, the research team becomes a health partner dedicated to their health and well-being. When patients join a clinical trial, they make an informed decision in their healthcare by weighing all available options in addition to routine treatments. Research participants know that they are contributing meaningfully and helping other patients like them. Where can I find more information about clinical trials at Renown Health? Renown Health’s mission is to make a genuine difference in the health and well-being of the communities we serve. Renown’s clinical trial portfolio offers leading care options to patients in northern Nevada, close to home, in a variety of specialties. Contact the Renown Clinical Research Office for more information on clinical trials available to you!

    Read More About What Does It Mean to Participate in a Clinical Trial?

    • Atención del cáncer
    • Testimonio de paciente
    • Ensayos clínicos

    Un diagnóstico de cáncer y una mudanza a Reno

    Michael Millman was all set to move to Reno from the Bay Area when he noticed a pimple-like growth on his forehead, and he decided to get biopsied "just in case." It was July 2020, less than six months into the COVID-19 pandemic, when Michael got the call that the biopsy came back cancerous. He was in shock. Still living in the Bay Area at the time, he immediately scheduled to have the basal cell carcinoma removed in August. After the removal, he thought he was in the clear, but a few months later, Michael noticed that his lymph nodes felt weird, and he even cut himself shaving because of some persistent swelling in the area. Given his recent history of skin cancer, Michael immediately scheduled an appointment with a specialist in the Bay Area. "I met with an ear, nose and throat doctor who suggested a fine needle biopsy of my lymph nodes, tongue and an MRI, both with and without contrast," Michael said. "I remember feeling dreadful and that I couldn't believe this was happening yet again." A Hard Decision Michael's squamous cell carcinoma, determined by the pathology report to be significantly influenced by the HPV virus, had metastasized to his lymph nodes on both sides of his neck, and his doctor said it could be stage four cancer. He remembers feeling like he was in quicksand, unsure if he should follow through with his move to Reno, or stay in the Bay Area for treatment. By now, it was early December 2020, and hospitals in the Bay Area and across the world were at limited capacity due to COVID-19. But, in what Michael describes as a positive twist of fate, the San Francisco ear, nose and throat provider he had seen about his biopsy results mentioned that he knew many providers in the oncology department at Renown, including Abhinand Peddada, MD. The San Francisco provider called Dr. Peddada's office with a referral, and Michael even remembers that Renown called him to hear more about his diagnosis before he even got the chance to call them "To be honest, I was feeling shut out in the Bay Area, and Dr. Peddada said he could help me expedite the treatment process," Michael said. "I finally felt a sense of relief." And so began Michael's 7-week chemoradiation cancer treatment program at Renown.

    Read More About A Cancer Diagnosis and a Move to Reno

Número de resultados encontrados: 24
Use esta navegación adicional para ir a las páginas siguientes. Use las teclas de tabulación e Intro para navegar por el menú1 Página n.º 2 Navegar a la página siguiente Página 1 de 2
Saltee a 24 resultados encontrados. Página 1 de 2